KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Cost of Revenue (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Cost of Revenue data on record, last reported at $10.3 million in Q3 2025.

  • For Q3 2025, Cost of Revenue fell 6.5% year-over-year to $10.3 million; the TTM value through Sep 2025 reached $46.9 million, up 15.15%, while the annual FY2024 figure was $42.0 million, 24.52% up from the prior year.
  • Cost of Revenue reached $10.3 million in Q3 2025 per NKTR's latest filing, down from $17.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $19.3 million in Q4 2024 and bottomed at $5.0 million in Q3 2022.
  • Average Cost of Revenue over 5 years is $8.9 million, with a median of $7.2 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: crashed 33.29% in 2022, then soared 165.52% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $6.2 million in 2021, then increased by 1.14% to $6.2 million in 2022, then grew by 16.85% to $7.3 million in 2023, then skyrocketed by 165.52% to $19.3 million in 2024, then tumbled by 46.75% to $10.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $10.3 million in Q3 2025, $17.3 million in Q1 2025, and $19.3 million in Q4 2024.